Angiex Private Investor Briefing - Virtual
Dear Investors,
For oncology investors, some of the most compelling opportunities emerge when a company moves from clinical hypothesis to clinical proof.
Angiex is advancing a novel approach to solid tumors with AGX101, an investigational Phase 1 antibody-drug conjugate (ADC) targeting TM4SF1 in tumor-associated vasculature and TM4SF1-expressing tumor cells.
Company Overview
AGX101 is designed to deliver its cytotoxic payload to both tumor blood vessels and tumor cells, creating a differentiated dual-targeting approach with potential across multiple solid tumor indications. Clinical data from 36 patients show exploratory evidence of on-tumor activity, with additional PET and ctDNA data expected to further characterize treatment response.
Why Investors Are Taking Notice
Clinical-stage asset: AGX101 is already in Phase 1 development.
Broad potential: TM4SF1 expression supports evaluation across multiple solid tumors.
Upcoming catalysts: Recommended Phase 2 dose selection, additional efficacy data, and FDA engagement represent key near-term milestones.
Financing opportunity: Angiex is raising a $10M top-off financing to advance AGX101 toward proof of concept.
Event Details:
Date: September 22
Time: 11:30 am - 12:30 pm ET
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Skylar Rallison at srallison@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com